



# Rational use of antibiotics in primary care

## CRISTIAN GONZÁLEZ GONZÁLEZ

Departamento de Medicina Preventiva y Salud Pública
Universidade de Santiago De Compostela

# Background

#### **Importance**

#### 2.3.2 Human burden of antibiotic resistance

The estimated human burden of infections due to the selected antibiotic-resistant bacteria is presented in Table 2.

The study confirmed that MRSA was, in 2007, the most common, single, multidrug-resistant bacterium in the EU as per the estimated number of cases of infection due to this bacterium. However, the sum of cases of antibiotic-resistant Gram-positive bacteria (mostly MRSA and vancomycin-resistant *Enterococcus faecium*) was comparable to that of antibiotic-resistant Gram-negative bacteria (third-generation cephalosporin-resistant *E. coli* and *K. pneumoniae*, and carbapenem-resistant *P. aeruginosa*).

Overall, it was estimated that in 2007 approximately 25 000 patients died from an infection due to any of the selected frequent antibiotic-resistant bacteria in the EU, Iceland and Norway. Notably, about two thirds of these deaths were caused by infections due to Gram-negative bacteria. In addition, infections due to any of the selected antibiotic-resistant bacteria resulted in approximately 2.5 million extra hospital days.

#### 2.3.3 Economic burden of antibiotic resistance

The estimated economic burden of infections due to the selected antibiotic-resistant bacteria is presented in Table 3.

Based on the number of extra hospital days, extra in-hospital costs in 2007 were estimated at more than EUR 900 million in the EU, Iceland and Norway.

Based on 2007 data, outpatient care costs were estimated at about EUR 10 million and productivity losses due to absence from work of infected patients were estimated at more than EUR 150 million, each year. Productivity losses due to patients who died from their infection were estimated at about EUR 450 million each year. Overall, societal costs of infections due to the selected antibiotic-resistant bacteria were estimated at about EUR 1.5 billion each year.





**TECHNICAL REPORT** 

bacterial challenge: time to react

A call to narrow the gap between Itidrug-resistant bacteria in the EU and


the development of new antibacterial agents

www.ecdc.europa.e

www.ema.europa.eu/pdfs/human/antimicrobial.../EMEA-576176-2009.pdf

# Background

#### **Importance**



### Antecedentes

Importancia



10

# La contención de la resistencia a los antimi El problema de la resis

Abril de 2005 Organización Mundial de la Salud Ginebra

# El problema de la resistencia a los antimicrobianos

a resistencia a los antimicrobianos (RAM) es uno los problemas de salud pública más graves del mun Muchos de los microbios (bacterias, virus, protozoos) a causan enfermedades infecciosas han dejado de resp der a los antimicrobianos de uso común (antibacteriar como los antibióticos, antivíricos y antiprotozoarios). El polema es tan grave que, si no se emprende una acconcertada a escala mundial, corremos el riesgo de gresar a la era preantibiótica, época en que morían a chos más niños que ahora por causa de enfermeda infecciosas y no era posible practicar intervencio quirúrgicas mayores debido al riesgo de infección. enfermedades infecciosas más importantes matan a referencia describado de concertada en secular de concertada de sinfecciosas más importantes matan a referencia de concertada de sinfecciosas más importantes matan a referencia de concertada de sinfecciosas más importantes matan a referencia de concertada de concertad

# El problema de la resistencia a los antimicrobianos

a resistencia a los antimicrobianos (RAM) es uno de los problemas de salud pública más graves del mundo. Muchos de los microbios (bacterias, virus, protozoos) que causan enfermedades infecciosas han dejado de responder a los antimicrobianos de uso común (antibacterianos, como los antibióticos, antivíricos y antiprotozoarios). El problema es tan grave que, si no se emprende una acción concertada a escala mundial, corremos el riesgo de regresar a la era preantibiótica, época en que morían muchos más niños que ahora por causa de enfermedades infecciosas y no era posible practicar intervenciones quirúrgicas mayores debido al riesgo de infección. Las enfermedades infecciosas más importantes matan a más

**Importance** 

Consumption-resistance

# THE LANCET

# Outpatient antibiotic use in Europe and association with resistance: a cross-national database study

Herman Goossens, Matus Ferech, Robert Vander Stichele, Monique Elseviers, for the ESAC Project Grou

#### Summary

Background Resistance to antibiotics is a major public-health problem and an recognised as the main selective pressure driving this resistance. Our aim was to and the association with resistance.

Methods We investigated outpatient antibiotic use in 26 countries in Eurocomparable distribution or reimbursement data, between Jan 1, 1997, and Dec 3 of defined daily doses (DDD) per 1000 inhabitants per day, according to WH classification and DDD measurement methodology. We assessed the ecological and antibiotic resistance rates using Spearman's correlation coefficients.

Findings Prescription of antibiotics in primary care in Europe varied greatly; (32 · 2 DDD per 1000 inhabitants daily) and the lowest was in the Netherlands (10 · We noted a shift from the old narrow-spectrum antibiotics to the new broad-spec striking seasonal fluctuations with heightened winter peaks in countries with I showed higher rates of antibiotic resistance in high consuming countries, consumption in southern and eastern Europe than in northern Europe.

Interpretation These data might provide a useful method for assessing public-hantibiotic use and resistance levels.





Figure 6: Correlation between penicillin use and prevalence of penicillin non-susceptible S pneumoniae AT, Austria; BE, Belgium; HR, Croatia; CZ, Czech Republic; DK, Denmark; FI, Finland; FR, France; DE, Germany; HU, Hungary; IE, Ireland; IT, Italy; LU, Luxembourg; NL, The Netherlands; PL, Poland; PT, Portugal; SI, Slovenia; ES, Spain; UK, England only.

Importance

Consumption-resistance

Relation of long-term consumption and resistance: co-selection of resistance.




Oteo J. 2008

# Background


Importance

Consumption-resistance





Importance

Consumption-resistance










# Background


**Importance** 

Consumption-resistance



**Importance** 

Consumption-resistance



**Importance** 

Consumption-resistance

Europe-Spain



#### RESEARCH

# Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: prospective study in 13 countries

C C Butler, professor, K Hood, director, T Verheij, professor, P Little, professor, H Melbye, professor, J Nuttall, senior trial manager, M J Kelly, statistician, S Mölstad, professor, M Godycki-Cwirko, physician, J Almirall, professor, A Torres, professor, D Gillespie, trainee statistician, U Rautakorpi, senior medical officer, Coenen, postdoctoral fellow, 1112 H Goossens, professor

<sup>1</sup>Department of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff CF14 4XN, Wales

<sup>2</sup>South East Wales Trials Unit (SEWTU), Department of Primary Care and Public Health, School of Medicine, Cardiff University, Heath Park, Cardiff, Wales

<sup>3</sup>University Medical Centre Utrecht, Julius Center for Health, Sciences and Primary Care, Universiteitswez 100. Stratenum.

#### ABSTRACT

Objective To describe variation in antibiotic prescribing for acute cough in contrasting European settings and the impact on recovery.

Design Cross sectional observational study with clinicians from 14 primary care research networks in 13 European countries who recorded symptoms on presentation and management. Patients followed up for 28 days with patient diaries.

Setting Primary care.

antibiotic prescribing is not associated with clinically important differences in recovery.

Trial registration Clinicaltrials.gov NCT00353951.

#### INTRODUCTION

Antibiotic resistance is a growing problem worldwide, with 10% of *Streptococcus pneumoniae* isolates recorded as non-susceptible to penicillin in 30 countries in 2007. There is wide variation in antibiotic prescribing for ambulant patients in Europe. We do not know if


Importance

Consumption-resistance

Europe-Spain

Primary care

#### Factors influencing the prescription of antibiotics by primary care doctors



Ripoll MA et al, Rev Esp Quimioter 2008;21(1):26-31

**Importance** 

Consumption-resistance


Europe-Spain

Primary care



Data distribution according to percentage of correct and incorrect prescription of antibiotic in Primary Care. *Med Clin*.

#### Centros de Salud



Saturno PJ. Med Clin (Barc)

Importance

Consumption-resistance

Europe-Spain

Primary Care

**SOLUTION** 

#### CONDITIONING FACTORS OF THE PRESCRIPTION OF ANTIBIOTICS IN Primary CARE:

Patient pressure

Industrial pressure

Fear / Uncertainty

Adherence to clinical guidelines

Access to clinical tests



Importance

Consumption-resistance

Europe-Spain

Primary Care

**SOLUTION** 

#### CONDITIONING FACTORS OF THE PRESCRIPTION OF ANTIBIOTICS IN Primary CARE:

Patient pressure

Industrial pressure

Fear / Uncertainty

Adherence to clinical guidelines

Access to clinical tests



Importance

Consumption-resistance

Europe-Spain

Primary Care

SOLUTION

| Patient pressure                 | Communication Skills |  |
|----------------------------------|----------------------|--|
| Fear / Uncertainty               |                      |  |
| Adherance to clinical guidelines |                      |  |

**Importance** 

Consumption-resistance

Europe-Spain

**Primary Care** 

**SOLUTION** 

#### PATIENT PRESSURE: COMMUNICATION SKILLS

Improve patient-doctor communication.

In 50% of the cases:

- .- NO detected complaints
- .- Patient and doctor. NO agreement

The patient can not describe his/her problem



Cancer Research
Campaign Psychological

practice.

This consensus statement addresses three issues:



#### he Toronto consensus

vart, Peter Maguire, Mack Lipkin, Dennis Novack,

substantial deficiencies when studied. Only a low proportion of visits with doctors include any patient education,<sup>15</sup> and a surprisingly high proportion of patients do not understand or remember what their physicians tell them about diagnosis and treatment.<sup>16</sup> Cultural differences also impede the work with patients.<sup>17</sup> <sup>18</sup>

Patient anxiety and dissatisfaction is related to uncertainty and lack of information, explanation, and feedback from the doctor. Yet doctors often misperceive the amount and type of information patients want. The language doctors use is often unclear, both as regards the use of jargon and in relation to a lack of the expected shared meanings of relatively common terms.<sup>20,23</sup>


Importance

Consumption-resistance

Europe-Spain

Primary Care

**SOLUTION** 



**Importance** 

Consumption-resistance

Europe-Spain

Primary Care

**SOLUTION** 

Little ASSERTIVITY

Low EMPATHY

No Point of AGREEMENT

Outcome:

Poor adherence to treatment

Consequences for the patient:

**Passivity** towards doctor's recommendations

Consequences for the physician:

**NO Closeness** to the patient

Burn out professional


**Importance** 

Consumption-resistance

Europe-Spain

Primary Care

**SOLUTION** 



**Importance** 

Consumption-resistance

Europe-Spain

Primary Care

**SOLUTION** 

ASSERTIVENESS
EMPATHY
NEGOTIATION



#### Results:

More adherence to treatment

Positive assessment of the physician

Consequences for the physician:

**Closeness** to the patient

Work satisfaction

THE CONSULTATION TIME DOES NOT INCREASE

**Importance** 

Consumption-resistance

Europe-Spain

**Primary Care** 

**SOLUTION** 

# Recuerde

- Los antibióticos no son eficaces contra los resfriados ni la gripe
- Tome los antibióticos de forma responsable y sólo cuando se los recete el médico
- Todos somos responsables de conseguir que los antibióticos sigan siendo eficaces



Cuando le receten antibióticos, siga las instrucciones del médico para minimizar el riesgo de desarrollar bacterias resistentes.

Si no sigue las instrucciones correctamente -si, por ejemplo, acorta la duración del tratamiento o toma una dosis menor o no toma los antibióticos en los momentos correctos que le haya prescrito el médico-, las bacterias pueden adquirir resistencia a los antibióticos.

Las bacterias resistentes pueden quedarse en su organismo y también pueden transmitirse a otras personas. Esto le expone a usted y expone a otros al riesgo de no responder a los antibióticos la próxima vez que los vuelva a necesitar.

- · Siga las instrucciones de su médico v tome los antibióticos cuándo y cómo él se lo indique
- · No utilice los antibióticos que le sobren
- · Pregunte a su médico o farmacéutico cómo debe tirar los antibióticos que le sobren







#### Cuando los necesite, utilice los antibióticos de manera responsable







#### Uso responsable de los antibióticos

#### Contribuya a mantener la eficacia de los antibióticos







FONDO EUROPEO DE DESARROLLO REGIONAL "Una manera de hacer Europa"



Si de sea más información sobre el uso responsable de los antibióticos, visite: http://antibiotic.ecdc.europa.eu




Importance

Consumption-resistance

Europe-Spain

Primary Care

**SOLUTION** 



**Importance** 

Consumption-resistance

Europe-Spain

**Primary Care** 

**SOLUTION** 

#### Delayed antibiotics for respiratory infections (Review)

Spurling GKP, Del Mar CB, Dooley L, Foxlee R



This is a reprine of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in *The Golman L*2011, Insect

1009//www.thecochranelibrary.com



blinding gave two trials (Chao 2008; Little 2005a) which blinded the outcome assessor to give an odds ratio for these two trials of 1.42 (95% CI 0.92 to 2.19). The one completely unblinded trial (Little 1997) gave an odds ratio of 1.49 (95% CI 0.70 to 3.19). In the *delayed* antibiotic arm 413 of participants were satisfied or very satisfied out of 473 participants (87.3%) compared to 387 out of 465 participants in the *no* antibiotics group (83.2%).

Delayed antibiotics for respiratory infections (Review)

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

benefit over *delayed* antibiotics in participants with sore throat and AOM. All strategies appear to have similar safety with no advantage found for *delayed* antibiotics over *no* antibiotics for disease complications. *Delay* and *no* antibiotic strategies dramatically reduce the use of antibiotics for ARTIs compared to *immediate* antibiotics. The least antibiotic use was in the *no* antibiotic group followed by *delay* and then *immediate*. The number needed to treat to prevent one antibiotic prescription using the delay strategy is 1.6 compared to *immediate* antibiotics. The number needed to treat to prevent one antibiotic prescription using a *no* antibiotic strategy compared to *delay* is 5.6. Patient satisfaction was highest in the *immediate* antibiotic group with 92.2% being satisfied or very satisfied with the consultation. The *delay* and *no* groups had similar quite high satisfaction rates at 87.3% and 83.2%, respectively.

Overall completeness and applicability of evidence

#### DISCUSSION

#### Summary of main results

Small differences were found between prescribing strategies for clinical outcomes with *immediate* antibiotics most likely to show

Dowell 2001; Little 2005a; Spiro 2006), the outcomes assessor was blinded but not the patient nor the care giver.

Otherwise, studies were well reported and appeared to be high quality.

#### Potential biases in the review process

Heterogeneity of RCTs is the main limitation of this review. Heterogeneity may have resulted from variable clinical presentations, differences in delay method, differences in antibiotic use and quality of included studies. Type I error is a concern when interpreting the results of this review, given the heterogeneity of results with multiple outcome measures. This is especially concerning for the comparisons for clinical outcomes between *delayed* and *immediate* antibiotic groups.

Agreements and disagreements with other

14

Importance

Consumption-resistance

Europe-Spain

Primary Care

**SOLUTION** 



#### Delayed antibiotics for respiratory infections (Review)

Spurling GKP, Del Mar CB, Dooley L, Foxlee R

|                             | EFFECTIVENESS | SECURITY  |
|-----------------------------|---------------|---|
| DEFERRED<br>Vs<br>IMMEDIATE | <b>≈</b>      | Increase in RAM <sup>M.N1</sup> Increase in resistances |

#### Diapositiva 25

a qué corresponde RAM? MALLAH ... NARMEEN; 06/10/2020 M.N1

Importance

Consumption-resistance


Europe-Spain

Primary Care

**SOLUTION** 

Patient pressure

Communication skills
Deferred Prescription
Supporting material




Fear / Uncertainty


**Deferred Prescription** 


| D   | ι   | M  | M  | J  | V  | S  |
|-----|-----|----|----|----|----|----|
|     |     |    |    |    | 1  | 2  |
| 3   | _4_ | 5  | 6  | 7  | 8  | 9  |
| 10  | 11  |    | 13 | 14 | 15 | 16 |
| 17  |     | 19 |    |    |    |    |
| 24  | 25  | 26 | 27 | 28 | 29 | 30 |
|     |     |    |    |    |    |    |
| . ' |     | I  | 1  | 1  | ı  | '  |

Adherence to clinical guidelines

Online course







El curso está dividido en 5 casos clínicos que servirán de introducción a los conceptos teóricos. Se realizará una prueba de evaluación al final con preguntas tipo test, en la que el alumno tendra la oportunidad de valorar su evolución contrastando sus propias respuestas antes y

#### Requerimientos exigidos para la acreditación

Haber superado en la prueba de evaluación final el 50 % de aciertos.



## Situación Actual

Importancia

Consumo-resistencias

Europa-España

At. Primaria

**SOLUCIONES** 

Presión del paciente

Habilidades de comunicación Prescripción Diferida Materiales de apoyo




Miedo / Incertidumbre Prescripción Diferida

| D  | L  | M  | M  | J  | V<br>1 | S<br>2 |
|----|----|----|----|----|--------|--------|
| 3  | 4  | 5  | 6  | 7  | 8      | 9      |
| 10 | 11 | -  | 13 | 14 | 15     | 16     |
| 17 | 18 | 19 | 20 | 21 | 22     | 23     |
| 24 | 25 | 26 | 27 | 28 | 29     | 30     |
|    |    |    |    |    |        |        |
| '  |    |    |    |    |        |        |

Adherencia a guías clínicas

Curso online







FONDO EUROPEO DE DESARROLLO REGIONAL "Una manera de hacer Europa"

# **MUCHAS GRACIAS POR SU ATENCIÓN**

cristian.gonzalez@usc.es